Digital Look

Welcome to Digital Look++,
you are not logged in

ReNeuron Group (RENE)

Pharma and Biotech

3.38p

2024-02-05 Suspension of Listing

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Mar-19	0.05	(17.23)	(44.11)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-20	6.07	(13.86)	(34.96)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-21	0.26	(13.41)	(29.00)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-22	0.40	(11.06)	(17.00)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-23	0.53	(6.66)	(9.50)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Mar-24	n/a	n/a	0.18p	18.8	n/a	n/a	n/a	0.0%
31-Mar-25	n/a	n/a	0.18p	18.8	n/a	n/a	n/a	0.0%

Directorate Change	17-Apr-2024	11:30	RNS
Appointment of Administrators	20-Mar-2024	15:43	RNS
Intention to Appoint Administrators	20-Mar-2024	12:30	RNS

ReNeuron reaches exosome research milestone	04-Sep-2023	ShareCast
Director dealings: Reneuron CFO makes share purc...	24-Jan-2023	ShareCast
ReNeuron shares tumble after first-half results	02-Dec-2022	ShareCast

Reneuron tests stem cell stroke treatment	03-Sep-2014	The Herald
ReNeuron unveils board shake-up as chairman move...	21-Jul-2011	The Scotsman
ReNeuron shares in healthy shape	04-Mar-2011	The Scotsman

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.